- Bloomberg•2 hours ago
Johnson & Johnson had a year for the record books -- it lost six of 2016’s seven largest jury verdicts in the U.S. over product defect claims. This year may be no better. The company is facing at least ...
- Zacks•21 hours ago
Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
- Motley Fool•21 hours ago
No tending needed for big pharma stocks Johnson & Johnson, Pfizer, and Novartis.
JNJ : Summary for Johnson & Johnson - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||124.75 x 200|
|Ask||127.50 x 500|
|Day's Range||125.15 - 126.14|
|52 Week Range||107.69 - 129.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.21|
|Dividend & Yield||3.20 (2.55%)|
|1y Target Est||N/A|